<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306852</url>
  </required_header>
  <id_info>
    <org_study_id>19990167</org_study_id>
    <nct_id>NCT00306852</nct_id>
  </id_info>
  <brief_title>Tube Versus Trabeculectomy (TVT) Study</brief_title>
  <official_title>Tube Versus Trabeculectomy (TVT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Tube Versus Trabeculectomy (TVT) Study is to compare the safety and
      efficacy of nonvalved tube shunt surgery to trabeculectomy with mitomycin C in patients with
      previous ocular surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma surgery is performed when further intraocular pressure (IOP) reduction is needed
      despite the use of maximum tolerated medical therapy and appropriate laser treatment.
      Trabeculectomy is generally used as the initial incisional surgical procedure in managing
      glaucoma. However, eyes in which trabeculectomy has failed are at greater risk of failure
      with subsequent filtering surgery. Wound modulation with antifibrotic agents, like mitomycin
      C (MMC) and 5-fluorouracil (5-FU), has been shown to increase the success rate of
      trabeculectomy in eyes that have undergone previous ocular surgery. Although antifibrotic
      agents have increased the likelihood of IOP control following filtering surgery, they have
      also increased the risk of complications. The prevalence of bleb leaks, bleb-related
      infections, and bleb dysesthesia associated with a perilimbal filtering bleb suggests the
      need to consider alternatives. Tube shunts (or glaucoma drainage implants) offer an
      alternative to trabeculectomy in the surgical management of glaucoma, and these devices have
      been growing in popularity in recent years.

      Practice patterns vary in the surgical management of glaucoma in eyes with previous ocular
      surgery. In 1996, Chen and colleagues conducted an anonymous survey of members of the
      American Glaucoma Society (AGS) and Japanese Glaucoma Society (JGS) to evaluate use of
      antifibrotic agents and tube shunts. The survey presented ten clinical situations requiring
      glaucoma surgical intervention. The majority of respondents (59-83%) preferred trabeculectomy
      with MMC for the clinical scenarios involving prior ocular surgery, although many of those
      surveyed elected to use a tube shunt, trabeculectomy with 5-FU, or trabeculectomy without an
      antifibrotic agent. In 2002, Joshi and associates re-administered the same survey to members
      of the AGS. Respondents still favored trabeculectomy with MMC, but the percentage usage of
      tube shunts had significantly increased. The greatest practice pattern shift was observed in
      patients with previous cataract and glaucoma surgery. In particular, selection of tube shunts
      as the preferred surgical approach increased from 7% to 22% in eyes with prior
      trabeculectomy, and increased from 8% to 22% in eyes with prior extracapsular or
      intracapsular cataract extraction.

      The lack of consensus among glaucoma surgeons regarding the use of tube shunts or
      trabeculectomy with an antifibrotic agent in eyes that have had prior cataract or glaucoma
      surgery likely relates to the fact that available clinical data has not shown one surgical
      procedure to be superior to the other. Similar surgical results have been reported with both
      glaucoma procedures in eyes with aphakia/pseudophakia and failed filters when studied
      separately. Success rates have ranged from 50% to 88% for tube shunts, and 48% to 86% for
      filtering surgery with an antifibrotic agent in case series studying aphakic/pseudophakic
      eyes. Success rates have ranged from 44% to 88% for tube shunts, and 61% to 100% for 5-FU and
      MMC trabeculectomy in eyes with failed filters. Comparable rates of severe complications have
      also been reported with tube shunt surgery and trabeculectomy with an adjunctive antifibrotic
      agent.

      The Tube Versus Trabeculectomy (TVT) Study was designed to prospectively compare the safety
      and efficacy of nonvalved tube shunt surgery and trabeculectomy with MMC. Patients with
      uncontrolled glaucoma who had prior cataract extraction with intraocular lens implantation
      and/or failed filtering surgery were enrolled in this multicenter clinical trial and
      randomized to placement of a 350 Baerveldt glaucoma implant (Advanced Medical Optics, Irvine,
      CA) or trabeculectomy with MMC (0.4 mg/ml for 4 minutes). The goal of this investigator
      initiated trial is to provide information that will assist in surgical decision-making in
      similar patient groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intraocular Pressure</measure>
    <time_frame>Baseline to 5 years</time_frame>
    <description>The data value from the Baseline visit and 5 year follow-up visit were combined. Specifically, values were calculated by subtracting the 5 Year Intraocular Pressure from the Baseline Intraocular Pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Complications</measure>
    <time_frame>5 years</time_frame>
    <description>Complications associated with both surgical procedures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>5 years</time_frame>
    <description>Visual acuity was measured by the total number of letters read (correctly) using a ETDRS eye chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperations for Glaucoma</measure>
    <time_frame>5 years</time_frame>
    <description>Reoperations for glaucoma was defined as additional glaucoma surgery requiring a return to the operating room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Supplemental Medical Therapy</measure>
    <time_frame>5 years</time_frame>
    <description>The number of supplemental glaucoma medications required in the Implant Group and Trabeculectomy Group at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure Rate</measure>
    <time_frame>5 years</time_frame>
    <description>Failure was prospectively defined as IOP greater than 21 mm Hg or less than 20 percent reduction below baseline on 2 consecutive follow-up visits after 3 months, IOP less than or equal to 5 mm Hg on 2 consecutive follow-up visits after 3 months, re-operation for glaucoma, or loss of light perception vision.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Trabeculectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trabeculectomy with mitomycin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baerveldt Implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Baerveldt implant</intervention_name>
    <description>Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
    <arm_group_label>Implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy with mitomycin C</intervention_name>
    <description>Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
    <arm_group_label>Trabeculectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 85 years

          -  Intraocular pressure greater than or equal to 18 mm Hg and less than or equal to 40 mm
             Hg

          -  Previous trabeculectomy, cataract extraction with intraocular lens implantation, or
             both

        Exclusion Criteria:

          -  Unwilling or unable to give consent, unwilling to accept randomization, or unable to
             return for scheduled protocol visits

          -  Pregnant or nursing women

          -  No light perception vision

          -  Active iris neovascularization or active proliferative retinopathy

          -  Iridocorneal endothelial syndrome

          -  Epithelial or fibrous downgrowth

          -  Aphakia

          -  Vitreous in the anterior chamber for which a vitrectomy is anticipated

          -  Chronic or recurrent uveitis

          -  Severe posterior blepharitis

          -  Unwilling to discontinue contact lens use after surgery

          -  Previous cyclodestructive procedure, scleral buckling procedure, or presence of
             silicone oil

          -  Conjunctival scarring precluding a trabeculectomy superiorly

          -  Need for glaucoma surgery combined with other ocular procedures (eg cataract surgery,
             penetrating keratoplasty, or retinal surgery) or anticipated need for additional
             ocular surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Gedde, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dale K Heuer, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard K Parrish, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <results_first_submitted>July 24, 2015</results_first_submitted>
  <results_first_submitted_qc>October 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2015</results_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Steven J. Gedde</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Trabeculectomy</keyword>
  <keyword>Tube shunt surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Trabeculectomy</title>
          <description>Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
        </group>
        <group group_id="P2">
          <title>Implant</title>
          <description>Baerveldt Implant
Baerveldt implant: Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trabeculectomy</title>
          <description>Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
        </group>
        <group group_id="B2">
          <title>Implant</title>
          <description>Baerveldt Implant
Baerveldt implant: Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.1" spread="9.9"/>
                    <measurement group_id="B2" value="70.9" spread="11.0"/>
                    <measurement group_id="B3" value="71.0" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intra-ocular pressure (IOP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.6" spread="503"/>
                    <measurement group_id="B2" value="25.1" spread="5.3"/>
                    <measurement group_id="B3" value="25.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GLAUCOMA MEDICATIONS</title>
          <units>number of medications used</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" spread="1.2"/>
                    <measurement group_id="B2" value="3.2" spread="1.1"/>
                    <measurement group_id="B3" value="3.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ETDRS (Early Treatment Diabetic Retinopathy Study) VISUAL ACUITY</title>
          <description>Numbers of letters read correctly on the ETDRS (Early Treatment Diabetic Retinopathy Study) chart.</description>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="19.6"/>
                    <measurement group_id="B2" value="62.7" spread="24.1"/>
                    <measurement group_id="B3" value="63.6" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Intraocular Pressure</title>
        <description>The data value from the Baseline visit and 5 year follow-up visit were combined. Specifically, values were calculated by subtracting the 5 Year Intraocular Pressure from the Baseline Intraocular Pressure.</description>
        <time_frame>Baseline to 5 years</time_frame>
        <population>Participants who completed 5 years of follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Trabeculectomy</title>
            <description>Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
          </group>
          <group group_id="O2">
            <title>Implant</title>
            <description>Baerveldt Implant
Baerveldt implant: Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intraocular Pressure</title>
          <description>The data value from the Baseline visit and 5 year follow-up visit were combined. Specifically, values were calculated by subtracting the 5 Year Intraocular Pressure from the Baseline Intraocular Pressure.</description>
          <population>Participants who completed 5 years of follow-up</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="5.9"/>
                    <measurement group_id="O2" value="14.4" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Complications</title>
        <description>Complications associated with both surgical procedures</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trabeculectomy</title>
            <description>Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
          </group>
          <group group_id="O2">
            <title>Implant</title>
            <description>Baerveldt Implant
Baerveldt implant: Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complications</title>
          <description>Complications associated with both surgical procedures</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EARLY POSTOPERATIVE COMPLICATIONS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LATE POSTOPERATIVE COMPLICATIONS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity</title>
        <description>Visual acuity was measured by the total number of letters read (correctly) using a ETDRS eye chart</description>
        <time_frame>5 years</time_frame>
        <population>Participants who complete 5 years of follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Trabeculectomy</title>
            <description>Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
          </group>
          <group group_id="O2">
            <title>Implant</title>
            <description>Baerveldt Implant
Baerveldt implant: Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Visual acuity was measured by the total number of letters read (correctly) using a ETDRS eye chart</description>
          <population>Participants who complete 5 years of follow-up</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PATIENTS WITH COMPLICATIONS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" spread="26"/>
                    <measurement group_id="O2" value="33" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PATIENTS WITHOUT COMPLICATIONS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="30"/>
                    <measurement group_id="O2" value="46" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reoperations for Glaucoma</title>
        <description>Reoperations for glaucoma was defined as additional glaucoma surgery requiring a return to the operating room.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trabeculectomy</title>
            <description>Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
          </group>
          <group group_id="O2">
            <title>Implant</title>
            <description>Baerveldt Implant
Baerveldt implant: Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Reoperations for Glaucoma</title>
          <description>Reoperations for glaucoma was defined as additional glaucoma surgery requiring a return to the operating room.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Supplemental Medical Therapy</title>
        <description>The number of supplemental glaucoma medications required in the Implant Group and Trabeculectomy Group at 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trabeculectomy</title>
            <description>Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
          </group>
          <group group_id="O2">
            <title>Implant</title>
            <description>Baerveldt Implant
Baerveldt implant: Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Supplemental Medical Therapy</title>
          <description>The number of supplemental glaucoma medications required in the Implant Group and Trabeculectomy Group at 5 years</description>
          <units>number of medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.5"/>
                    <measurement group_id="O2" value="1.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Failure Rate</title>
        <description>Failure was prospectively defined as IOP greater than 21 mm Hg or less than 20 percent reduction below baseline on 2 consecutive follow-up visits after 3 months, IOP less than or equal to 5 mm Hg on 2 consecutive follow-up visits after 3 months, re-operation for glaucoma, or loss of light perception vision.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trabeculectomy</title>
            <description>Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
          </group>
          <group group_id="O2">
            <title>Implant</title>
            <description>Baerveldt Implant
Baerveldt implant: Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Failure Rate</title>
          <description>Failure was prospectively defined as IOP greater than 21 mm Hg or less than 20 percent reduction below baseline on 2 consecutive follow-up visits after 3 months, IOP less than or equal to 5 mm Hg on 2 consecutive follow-up visits after 3 months, re-operation for glaucoma, or loss of light perception vision.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Trabeculectomy</title>
          <description>Trabeculectomy with mitomycin C
Trabeculectomy with mitomycin C: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant</description>
        </group>
        <group group_id="E2">
          <title>Implant</title>
          <description>Baerveldt Implant
Baerveldt implant: Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYCARDIAL INFRACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CANCER</sub_title>
                <description>Specific Cancer type or cause - unknown.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>UNKNOWN CAUSE OF DEATH</sub_title>
                <description>Study Team/Coordinating Center was unable to obtain the specific cause of death for 12 Subjects.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BONE CANCER</sub_title>
                <description>CLASSIFICATION UNKNOWN</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF THE TRACHEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>LUNG CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CORONARY ARTERY BYPASS SURGERY</sub_title>
                <description>MORE SPECIFIC CAUSE OF DEATH UNAVAILABLE.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CHOROIDAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>SHALLOW OR FLAT ANTERIOR CHAMBER</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>WOUND LEAK</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>HYPHEMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>AQUEOUS MISDIRECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>SUPRACHOROIDAL HEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>VITREOUS HEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>DECOMPRESSION RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>CYSTOID MACULAR EDEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>PERSISTENT CORNEAL EDEMA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>DYSESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>PERSISTENT DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>ENCAPSULATED BLEB</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>BLEB LEAK</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>HYPOTONY MACULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>TUBE EROSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>ENDOPHTHALMITIS/BLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>CHRONIC OR RECURRENT IRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>TUBE OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>CORNEAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>SERIOUS COMPLICATIONS</sub_title>
                <description>Serious complications were defined as postoperative complications requiring a re-operation to manage the complication and/or resulting in loss of 2 or more lines of Snellen VA.</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Gedde</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-326-6435</phone>
      <email>sgedde@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

